Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM combination therapy for diabetic microangiopathy complications
ChiCTR-IPR-15007068Phase 4Not yet recruiting
- Sponsor
- Chengdu University of Traditional Chinese Medicine
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of qiming granule, Keluoxin and Mudan Granules in diabetic retinopathy (DR), diabetic glomerulosclerosis, diabetic polyneuropathy (DPN) and 1 more (4 arms), sponsored by Chengdu University of Traditional Chinese Medicine. Primary endpoints: Best corrected visual acuity, TCM syndrome evaluation and 6 more. Planned start Jan 2014; status: not yet recruiting.
02
Drugs
qiming granuleKeluoxinMudan Granules
03
Conditions
diabetic retinopathy (DR)diabetic glomerulosclerosisdiabetic polyneuropathy (DPN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15007068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007068.